BiOneCure Therapeutics, Inc. entered into a strategic collaboration with Nanjing Leads Biolabs to develop a range of innovative anti-drug conjugates (ADCs) for treating solid tumors.

BiOneCure is a clinical-stage biopharmaceutical company dedicated to developing next-generation ADCs, while Leads Biolabs is a clinical-stage biotech focused on the research, development, and commercialization of next-generation tumor immunotherapy antibody drugs.

BiOneCure has developed several ADC payload-linker platforms, and its first product, BIO-106, an anti-Trop-2 ADC, is currently in a Phase I clinical study.

Meanwhile, Leads Biolabs has established a rich portfolio of more than 20 novel mono- or bispecific antibody drug projects to fulfill unmet medical needs. The two companies’ technologies are highly complementary, and the collaboration aims to significantly promote the R&D and product development capabilities of both parties.

“We are excited to collaborate with Leads Biolabs to develop ADC drugs,” said Haifeng Bao, CEO of BiOneCure. “Through this collaboration, we aim to accelerate innovation and development in the ADC field and provide better treatment options for patients.”

“We believe that BiOneCure has leading ADC technology platforms, and their ADC molecule is in the clinical stage,” said Xiaoqiang Kang, founder and chairman of Leads Biolabs. “Leads Biolabs is a clinical-stage antibody new drug company, with multiple antibody technology platforms. We are convinced that this collaboration will greatly expand the innovative R&D capabilities of both parties.”